Two risk factors for hypozincemia in diabetic [beta]-thalassemia patients: Hepatitis C and deferasirox

Hypozincemia is a prevalent adverse consequence in diabetes mellitus (DM) and [beta]-Thalassemia patients. We aimed to evaluate the level of serum zinc in [beta]-thalassemia patients with DM and a risk assessment for hypozincemia. The study population included transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT) with overt DM (fasting plasma glucose (FPG) [greater than or equal to]126 mg/dL, and/or 2-h plasma glucose[greater than or equal to]200 mg/dL). Serum zinc concentration was measured by the colorimetric method, and the values below 70 [mu]g/dL were defined as hypozincemia. Myocardial and liver T2*-weighted magnetic resonance imaging (MRI T2*, millisecond [ms]) were valued by a free contrast MRI. The demographic, clinical, paraclinical, and laboratory data were also recorded. The data belonged to the period from December 2018 until December 2020. Of 64 diabetic [beta]-thalassemia patients, 41 cases had zinc data in their medical files (aged 38 ± 9 years, 48.8% female). 78.05% of patients (n = 32) were TDT, and 21.95% were NTDT (n = 9). The mean ± standard deviation of zinc level was 110.2 ± 127.6 [mu]g/dL. The prevalence of hypozincemia was 9.76%, 95% confidence interval [CI] 0.27 to 19.24 (four cases). After controlling age, the odds of hypozincemia for using deferasirox (DFX) was 8.77, 95% CI 0.60 to 127.1. In [beta]-thalassemia patients, the age-adjusted risk of hypozincemia was calculated at 15.85, 95% CI 0.47 to 529.3 for hepatitis C. The adjusted risk of hypozincemia based on age for antacid use was 6.34, 95% CI 0.39 to 102.7. In light of this study, as well as hepatitis C, using DFX and antacids is associated with a high risk of hypozincemia amid diabetic [beta]-thalassemia cases. However, upward bias should be taken into consideration.